Clinical trials: Thalidomide
Multiple Myeloma
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free…
- Trial name
- Cassiopeia (NCT02541383)
- Testing
- Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Daratumumab
- Where
- 107 sites in Belgium, France and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004088
- Testing
- filgrastim, recombinant interferon alfa, busulfan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- City of Hope Medical Center
Hodgkin Disease
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).
- Trial name
- NCT00540007
- Testing
- Lenalidomide
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to…
- Trial name
- NCT00458705
- Testing
- bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
Study Objectives 1. To evaluate the efficacy of the combination of dexamethasone (Decadron®), thalidomide (Thalomid®), and lenalidomide (Revlimid®) as therapy for patients with relapsed or refractory multiple myeloma (MM) who…
- Trial name
- DexTR (NCT00538824)
- Testing
- dexamethasone, thalidomide, lenalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
The primary objective of this study is to: Determine the maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients…
- Trial name
- Thal/Mel/Vel (NCT01242267)
- Testing
- Thalidomide+Melphalan +Bortezomib+stem cell transplant
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Hackensack Meridian Health
Glioma
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
This study will examine the safety and effectiveness of peginterferon alpha-2b (PEG-Intron) alone and together with thalidomide in patients with gliomas (a type of brain tumor).
- Trial name
- NCT00047879
- Testing
- PEG-interferon alfa-2b, Thalidomide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00090870
- Testing
- PEG-interferon alfa-2b, GM-CSF, thalidomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Multiple Myeloma
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial.
- Trial name
- NCT00083551
- Testing
- Thalidomide, Ara-C, BCNU
- Where
- United States
- Volunteers
- 668 people
- Sponsor
- University of Arkansas
Multiple Myeloma
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma.
- Trial name
- NCT00097981
- Testing
- Thalidomide, Dexamethasone, DOXIL
- Where
- 58 sites in United States
- Volunteers
- 225 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Leukemia
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00096018
- Testing
- fludarabine phosphate, thalidomide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Roswell Park Cancer Institute
Relapsed and Refractory Multiple Myeloma
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of Ixazomib administered orally in participants with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT00932698
- Testing
- Ixazomib
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.